Last reviewed · How we verify
Humulin®R
At a glance
| Generic name | Humulin®R |
|---|---|
| Sponsor | Biocon Limited |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes (PHASE2)
- Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes (PHASE1, PHASE2)
- Pharmacokinetic and Pharmacodynamic Effects of Insulex® R in Comparison to Humulin® R in Healthy Subjects (PHASE1)
- Insulin and Abatacept in Recently-diagnosed Type 1 Diabetes (PHASE2)
- Study of Nasal Insulin to Fight Forgetfulness - Device Study (PHASE2)
- SNIFF - Combo INI+EMPA Trial (PHASE2)
- The Accuracy of Continuous Glucose Monitoring Systems in Critically Ill Patients
- A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Humulin®R CI brief — competitive landscape report
- Humulin®R updates RSS · CI watch RSS
- Biocon Limited portfolio CI